Latest Gilead Sciences News & Updates

See the latest news and media coverage for Gilead. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gilead Sciences (Gilead)

Biopharmaceutical company focused on virology, oncology and inflammation

gilead.com

Headquarters: Foster City, United States
Founded year: 1987
Company type: Public company
Number of employees: 10,000+

Last updated Today

Latest news about Gilead Sciences (Gilead)

In short: Gilead expanded its oncology and HIV portfolios through major acquisitions and regulatory milestones while raising its 2026 sales guidance.

Company announcements

Today Gilead

Gilead's Trodelvy approved by EC for first-line metastatic TNBC

The approval is for patients not candidates for PD-L1 inhibitors, based on ASCENT-03 study showing PFS benefit.

June 18 Gilead

Gilead marks one year of twice-yearly HIV prevention medication

The drug was approved in the US and EU, and has reached over 120 countries via licensing deals and access programs.

June 15 Gilead

Gilead's once-weekly oral HIV prevention pill application accepted

The FDA assigned a PDUFA date of February 2, 2027, and if approved, it would be the first long-acting oral PrEP option.

June 12 Gilead

Gilead donates remdesivir to support Ebola response in Uganda

The donation of over 2,000 vials will aid in treating the Ebola Bundibugyo virus disease under compassionate use.

Media coverage

June 17 GuruFocus

Insider Sell: Johanna Mercier Sells 3,000 Shares of Gilead Scien

Following this transaction, the insider now owns 124,234 shares of the company. Gilead Sciences Inc (GILD) is a biopharmaceutical company that discovers, develops, and commercializes...

June 16 Investing.com

Gilead Sciences CFO Andrew Dickinson sells stock worth $376,200 By Investing.com

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks...

June 15 Pharmaphorum

FDA starts kicks off review of Gilead's weekly HIV pill

The FDA has started a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), and is due to deliver its verdict by...

June 15 Seeking Alpha

Gilead weekly Yeztugo HIV pill sNDA accepted by FDA

Gilead's weekly Yeztugo (lenacapavir) for HIV PrEP has been accepted for FDA review with a Feb. 2, 2027 action date.

Never miss news about Gilead

Track Gilead and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gilead competitors & trending companies

Browse news for competitors to Gilead and other trending companies.